Canada Approves Apotex's Bid to Sell Generic Version of Wegovy

Dow Jones06-30

OTTAWA--Canadian regulators approved Apotex's bid to manufacture a generic version of the weight-loss drug Wegovy.

Canada's health department, which is in charge of drug approvals, said Monday it authorized Apotex's bid following a review of evidence from the company that meets the regulator's criteria for generic drugs. Wegovy is produced by Danish drug maker Novo Nordisk.

In April, Canada became the first Group of Seven economy to approve a generic version of semaglutide. At that time, Canada authorized a generic version of Ozempic developed by Dr. Reddy's Laboratories.

Canada said the semaglutide injection it approved is to be used once a week for patients 12 years and over as a supplement to a reduced-calorie diet and increased physical activity for chronic weight management.

Canada's health department said many generic medication are anywhere from 45% to 90% cheaper than the brand-name versions.

Write to Paul Vieira at paul.vieira@wsj.com

(END) Dow Jones Newswires

June 29, 2026 17:34 ET (21:34 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2647071953?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-30 05:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2647071953","market":"sg","top_or_hot":-1,"title":"Canada Approves Apotex's Bid to Sell Generic Version of Wegovy","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  OTTAWA--Canadian regulators approved Apotex's bid to manufacture a generic version of the weight-loss drug Wegovy. \n</p>\n<p>\n  Canada's health department, which is in charge of drug approvals, said Monday it authorized Apotex's bid following a review of evidence from the company that meets the regulator's criteria for generic drugs. Wegovy is produced by Danish drug maker <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>. \n</p>\n<p>\n  In April, Canada became the first Group of Seven economy to approve a generic version of semaglutide. At that time, Canada authorized a generic version of Ozempic developed by Dr. Reddy's Laboratories. \n</p>\n<p>\n  Canada said the semaglutide injection it approved is to be used once a week for patients 12 years and over as a supplement to a reduced-calorie diet and increased physical activity for chronic weight management. \n</p>\n<p>\n  Canada's health department said many generic medication are anywhere from 45% to 90% cheaper than the brand-name versions. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Paul Vieira at paul.vieira@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 29, 2026 17:34 ET (21:34 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Canada Approves Apotex's Bid to Sell Generic Version of Wegovy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCanada Approves Apotex's Bid to Sell Generic Version of Wegovy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-06-30 05:34</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  OTTAWA--Canadian regulators approved Apotex's bid to manufacture a generic version of the weight-loss drug Wegovy. \n</p>\n<p>\n  Canada's health department, which is in charge of drug approvals, said Monday it authorized Apotex's bid following a review of evidence from the company that meets the regulator's criteria for generic drugs. Wegovy is produced by Danish drug maker <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>. \n</p>\n<p>\n  In April, Canada became the first Group of Seven economy to approve a generic version of semaglutide. At that time, Canada authorized a generic version of Ozempic developed by Dr. Reddy's Laboratories. \n</p>\n<p>\n  Canada said the semaglutide injection it approved is to be used once a week for patients 12 years and over as a supplement to a reduced-calorie diet and increased physical activity for chronic weight management. \n</p>\n<p>\n  Canada's health department said many generic medication are anywhere from 45% to 90% cheaper than the brand-name versions. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Paul Vieira at paul.vieira@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 29, 2026 17:34 ET (21:34 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVOH","symbol_name":"Novo Nordisk A/S B Shares ADRhedged","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2647071953","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2647071953","pubTimestamp":1782768840,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"OTTAWA--Canadian regulators approved Apotex's bid to manufacture a generic version of the weight-loss drug Wegovy.Canada's health department, which is in charge of drug approvals, said Monday it autho","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVOH":"Novo Nordisk A/S B Shares ADRhedged","BK4532":"文艺复兴科技持仓","NVO":"诺和诺德","BK4588":"碎股","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BK4599":"减肥药","BK4007":"制药","NVOX":"2倍做多NVO ETF-Defiance","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","BK4585":"ETF&股票定投概念"},"translate_title":"加拿大批准Apotex出售Wegovy仿制药的投标","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVOH":0.6,"NVO":1.87,"NVOX":0.6},"content_text":"OTTAWA--Canadian regulators approved Apotex's bid to manufacture a generic version of the weight-loss drug Wegovy. \n\n\n  Canada's health department, which is in charge of drug approvals, said Monday it authorized Apotex's bid following a review of evidence from the company that meets the regulator's criteria for generic drugs. Wegovy is produced by Danish drug maker Novo Nordisk. \n\n\n  In April, Canada became the first Group of Seven economy to approve a generic version of semaglutide. At that time, Canada authorized a generic version of Ozempic developed by Dr. Reddy's Laboratories. \n\n\n  Canada said the semaglutide injection it approved is to be used once a week for patients 12 years and over as a supplement to a reduced-calorie diet and increased physical activity for chronic weight management. \n\n\n  Canada's health department said many generic medication are anywhere from 45% to 90% cheaper than the brand-name versions. \n\n\n \n\n\n  Write to Paul Vieira at paul.vieira@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 29, 2026 17:34 ET (21:34 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.0","shortVersion":"4.45.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2647071953","isCrawlerRequest":true}